3D Printing for Neural Repair: Bridging the Gap in Regenerative Medicine
St Clair-Glover M., Yue Z., Dottori M.
Animal Study, published in Adv Mater (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Adv Mater (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40736088
- PMCID
- PMC12422090
- DOI
- 10.1002/adma.202507590
- Citations
- 4
Abstract (original English)
Neurological disorders impose a substantial global health burden, compounded by the limited regenerative capacity of neural tissues and the absence of curative therapies. 3D bioprinting offers a transformative tool to model, replace, and regenerate neural tissues through the precise spatial organization of cells and biomaterials. In this perspective article, recent advances are examined in: i) the development of in vitro neural platforms for disease modeling and drug screening; ii) bioprinted acellular scaffolds designed to guide endogenous neural repair; and iii) cell-laden constructs that aim to replace or reconstruct damaged neural circuits. Key translational challenges are critically evaluated, including vascularization, immune integration, functional maturation, and replicating the complex cytoarchitectures of native neural tissues. Highlighting representative preclinical studies and emerging biofabrication technologies, we discuss how innovations in biomaterials, scaffold design, stem cell biology, and neuroengineering are converging to overcome existing limitations. Through tailored strategies and interdisciplinary collaboration, 3D bioprinting is poised to redefine therapeutic paradigms and drive the development of next-generation, personalized regenerative therapies for neurological diseases and injuries.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.